Teleflex (TFX) 10-Q 3 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Apr. 01, 2018	Apr. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 1, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Central Index Key	96,943
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		45,543,546

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Income Statement [Abstract]
Net revenues	$ 587,230	$ 487,881
Cost of goods sold	255,960	232,321
Gross profit	331,270	255,560
Selling, general and administrative expenses	215,337	163,969
Research and development expenses	26,027	17,827
Restructuring charges	3,063	12,945
Income from continuing operations before interest, loss on extinguishment of debt and taxes	86,843	60,819
Interest expense	25,943	17,726
Interest income	(273)	(169)
Loss on extinguishment of debt	0	5,582
Income from continuing operations before taxes	61,173	37,680
Taxes (benefit) on income from continuing operations	6,242	(2,669)
Income from continuing operations	54,931	40,349
Operating income (loss) from discontinued operations	1,235	(282)
Tax benefit on income (loss) from discontinued operations	(18)	(103)
Income (loss) from discontinued operations	1,253	(179)
Net income	$ 56,184	$ 40,170
Basic:
Income from continuing operations (in dollars per share)	$ 1.21	$ 0.90
Income (loss) from discontinued operations (in dollars per share)	0.03	(0.01)
Net income (in dollars per share)	1.24	0.89
Diluted:
Income from continuing operations (in dollars per share)	1.18	0.87
Loss from discontinued operations (in dollars per share)	0.02	(0.01)
Net income (in dollars per share)	1.20	0.86
Dividends per share (in dollars per share)	$ 0.34	$ 0.34
Weighted average common shares outstanding
Basic (in shares)	45,329	44,893
Diluted (in shares)	46,695	46,615

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 56,184	$ 40,170
Other comprehensive income, net of tax:
Foreign currency translation, net of tax of $(5,872) and $(7,089)	81,188	46,982
Pension and other postretirement benefit plans adjustment, net of tax of $(234) and $(532)	881	890
Derivatives qualifying as hedges, net of tax of $(211) and $(555)	621	1,728
Other comprehensive income, net of tax:	82,690	49,600
Comprehensive income	$ 138,874	$ 89,770

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (5,872)	$ (7,089)
Pension and other postretirement benefits plans adjustment, tax	(234)	(532)
Derivatives qualifying as hedges, tax	$ (211)	$ (555)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Apr. 01, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 378,872	$ 333,558
Accounts receivable, net	359,140	345,875
Inventories, net	403,676	395,744
Prepaid expenses and other current assets	52,998	47,882
Prepaid taxes	7,234	5,748
Assets held for sale	3,239	0
Total current assets	1,205,159	1,128,807
Property, plant and equipment, net	389,519	382,999
Goodwill	2,264,447	2,235,592
Intangible assets, net	2,390,555	2,383,748
Deferred tax assets	3,969	3,810
Other assets	46,951	46,536
Total assets	6,300,600	6,181,492
Current liabilities
Current borrowings	77,500	86,625
Accounts payable	84,686	92,027
Accrued expenses	101,128	96,853
Current portion of contingent consideration	162,061	74,224
Payroll and benefit-related liabilities	80,418	107,415
Accrued interest	20,503	6,165
Income taxes payable	13,500	11,514
Other current liabilities	11,978	9,053
Total current liabilities	551,774	483,876
Long-term borrowings	2,154,217	2,162,927
Deferred tax liabilities	616,711	603,676
Pension and postretirement benefit liabilities	117,874	121,410
Noncurrent liability for uncertain tax positions	12,628	12,296
Noncurrent contingent consideration	119,796	197,912
Other liabilities	167,100	168,864
Total liabilities	3,740,100	3,750,961
Commitments and contingencies
Total shareholders' equity	2,560,500	2,430,531
Total liabilities and shareholders' equity	$ 6,300,600	$ 6,181,492

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Cash flows from operating activities of continuing operations:
Net income	$ 56,184	$ 40,170
Adjustments to reconcile net income to net cash provided by operating activities:
(Income) loss from discontinued operations	(1,253)	179
Depreciation expense	14,832	14,180
Amortization expense of intangible assets	37,816	18,785
Amortization expense of deferred financing costs and debt discount	1,178	1,406
Loss on extinguishment of debt	0	5,582
Fair value step up of acquired inventory sold	0	7,832
Changes in contingent consideration	9,592	179
Stock-based compensation	4,787	4,240
Deferred income taxes, net	(1,472)	(3,081)
Other	(1,272)	(2,703)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(3,402)	18,691
Inventories	32	(5,322)
Prepaid expenses and other current assets	(3,406)	(1,224)
Accounts payable and accrued expenses	(27,185)	2,696
Income taxes receivable and payable, net	417	(10,670)
Net cash provided by operating activities from continuing operations	86,848	90,940
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(15,747)	(12,894)
Proceeds from sale of assets	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(3,684)	(975,524)
Net cash used in investing activities from continuing operations	(19,431)	(982,086)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	1,194,500
Reduction in borrowings	(18,500)	(138,251)
Debt extinguishment, issuance and amendment fees	(74)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	1,400	(505)
Payments for contingent consideration	(91)	(79)
Dividends paid	(15,447)	(15,287)
Net cash provided by (used in) financing activities from continuing operations	(32,712)	1,021,264
Cash flows from discontinued operations:
Net cash used in operating activities	(206)	(266)
Net cash used in discontinued operations	(206)	(266)
Effect of exchange rate changes on cash and cash equivalents	10,815	15,488
Net increase in cash and cash equivalents	45,314	145,340
Cash and cash equivalents at the beginning of the period	333,558	543,789
Cash and cash equivalents at the end of the period	378,872	689,129
Non cash financing activities of continuing operations:
Settlement and exchange of convertible notes with common or treasury stock	0	958
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$ 17,872	$ 19,311

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning Balance at Dec. 31, 2016					$ (438,717)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 40,170
Other comprehensive income	49,600
Ending Balance at Apr. 02, 2017					(389,117)
Beginning Balance (in shares) at Dec. 31, 2017		46,871				1,704
Beginning Balance at Dec. 31, 2017	2,430,531	$ 46,871	$ 591,721	$ 2,285,886	(265,091)	$ (228,856)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	56,184			56,184
Cash dividends ($0.34 per share)	(15,447)			(15,447)
Other comprehensive income	82,690				82,690
Settlements of note hedges associated with convertible notes and warrants (in shares)						(132)
Settlements of note hedges associated with convertible notes and warrants	(12)		(17,884)			$ 17,872
Shares issued under compensation plans (in shares)		(97)				(43)
Shares issued under compensation plans	4,122	$ 97	992			$ 3,033
Deferred compensation (in shares)						(8)
Deferred compensation	322					$ 322
Ending Balance (in shares) at Apr. 01, 2018		46,968				1,521
Ending Balance at Apr. 01, 2018	$ 2,560,500	$ 46,968	$ 574,829	$ 2,328,733	$ (182,401)	$ (207,629)

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34

Basis of presentation

Basis of presentation	3 Months Ended
	Apr. 01, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair presentation of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017 .

New accounting standards

New accounting standards	3 Months Ended
	Apr. 01, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. The Company adopted the new standard on January 1, 2018 using the modified retrospective method applied to all contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $0.3 million increase to the Company's opening balance of retained earnings on the adoption date. Also in connection with the adoption of the new standard, the Company reclassified the reserve for product returns from a contra-receivable to a liability. The reserve for returns and allowances was $4.4 million at April 1, 2018. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018 using the modified retrospective method of adoption; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings on the adoption date. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated results of operations and financial position. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits for a reclassification of these amounts to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted for reporting periods for which financial statements have not yet been issued. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues

Net revenues	3 Months Ended
	Apr. 01, 2018
Deferred Revenue Disclosure [Abstract]
Net revenues	Net revenues The Company primarily generates revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with the Company’s customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when the Company’s products are shipped from the manufacturing facility. The Company markets and sells products through its direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers such as pharmacies, which comprised 87% , 9% and 4% of consolidated net revenues, respectively, for the three months ended April 1, 2018. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. Payment is generally due 30 days from the date of invoice. The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; and (5) the Company classifies shipping and handling costs within cost of goods sold. The amount of consideration the Company receives and revenue the Company recognizes varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. The Company’s policy is to accept returns only in cases in which the product is defective and covered under the Company’s standard warranty provisions. When the Company gives customers the right to return products, the Company estimates the expected returns based on an analysis of historical experience. The reserve for returns and allowances was $4.4 million and $4.7 million as of April 1, 2018 and April 2, 2017, respectively. In estimating customer rebates, the Company considers the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers and other relevant information as the Company has a history of providing similar rebates on similar products to similar customers. The reserve for customer incentive programs, including customer rebates, was $13.2 million and $10.1 million at April 1, 2018 and April 2, 2017, respectively. The Company expects the amounts subject to the reserve as of April 1, 2018 to be paid within 90 days subsequent to period-end. The following table disaggregates revenue by global product category for the three months ended April 1, 2018 and April 2, 2017. Three Months Ended April 1, 2018 April 2, 2017 Revenue by global product category (1) (2) (Dollars in thousands) Vascular access $ 144,241 $ 130,022 Anesthesia 85,418 81,205 Interventional 71,680 43,966 Surgical 85,632 87,304 Interventional urology 42,300 — OEM 45,872 43,346 Other (3) 112,087 102,038 Net revenues $ 587,230 $ 487,881 (1) The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined based on the particular products sold by the segments, and its non-North American reportable segments are defined based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above. (2) Products included within certain of the product categories listed in the table above differ from those included within the similarly named reportable segment. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which those sales originated, while the classification of products within the product categories listed above includes sales originating from multiple call points within the customer's organization. (3) Other revenues in the table above comprise the Company’s respiratory, urology and cardiac product categories.

Acquisitions

Acquisitions	3 Months Ended
	Apr. 01, 2018
Business Combinations [Abstract]
Acquisitions	Acquisitions During 2017, the Company completed several acquisitions; the largest of which were Vascular Solutions, Inc. ("Vascular Solutions") and NeoTract, Inc. ("NeoTract"), which are summarized below. The fair value of the consideration transferred for the 2017 acquisitions was $2.0 billion . Vascular Solutions On February 17, 2017, the Company acquired Vascular Solutions, a medical device company that developed and marketed products for use in minimally invasive coronary and peripheral vascular procedures. The aggregate consideration paid by the Company in connection with the acquisition was $975.5 million . NeoTract On October 2, 2017, the Company acquired NeoTract, a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The fair value of consideration transferred by the Company was $975.2 million , which included initial payments of $725.6 million in cash less a favorable working capital adjustment of $1.4 million (payment for which remains outstanding as of April 1, 2018) and $251.0 million in estimated fair value of contingent consideration related to revenue-based milestones. The contingent consideration liability represents the estimated fair value of the Company’s obligations, under the acquisition agreement, to make additional payments of up to $ 375 million in the aggregate if specified sales goals through the end of 2020 are achieved. Financial information of NeoTract is primarily presented within the Interventional Urology North America operating segment, which is included in the "all other" category in the Company's presentation of segment information. The Company is continuing to evaluate the initial purchase price allocations in connection with its acquisition of NeoTract, and further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities, certain intangible assets and goodwill. Pro forma combined financial information The following unaudited pro forma combined financial information for the three months ended April 2, 2017 gives effect to the Vascular Solutions and NeoTract acquisitions as if they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended April 2, 2017 (Dollars and shares in thousands, except per share) Net revenue $ 533,318 Net income $ 37,108 Basic earnings per common share: Net income $ 0.83 Diluted earnings per common share: Net income $ 0.80 Weighted average common shares outstanding: Basic 44,893 Diluted 46,615 The unaudited pro forma combined financial information presented above includes the accounting effects of the Vascular Solutions and NeoTract acquisitions, including, to the extent applicable, amortization charges from acquired intangible assets; adjustments for depreciation of property, plant and equipment; interest expense; the revaluation of inventory; and the related tax effects. The unaudited pro forma financial information also includes non-recurring charges specifically related to the Vascular Solutions and NeoTract acquisitions.

Restructuring (credits) charges

Restructuring (credits) charges	3 Months Ended
	Apr. 01, 2018
Restructuring and Related Activities [Abstract]
Restructuring charges	Note 5 — Restructuring charges The following tables provide information regarding restructuring charges recognized by the Company for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 Termination benefits Other restructuring costs (2) Total (Dollars in thousands) 2016 Footprint realignment plan $ 1,955 $ 194 $ 2,149 2014 Footprint realignment plan 116 8 124 Other restructuring programs (1) 585 205 790 Restructuring charges $ 2,656 $ 407 $ 3,063 Three Months Ended April 2, 2017 Termination benefits Other restructuring costs (2) Total (Dollars in thousands) Vascular Solutions Integration Program $ 4,482 $ — $ 4,482 EMEA Restructuring Program 7,121 — 7,121 2016 Footprint realignment plan 539 (30 ) 509 2014 Footprint realignment plan 303 8 311 Other restructuring programs (3) 305 217 522 Restructuring charges $ 12,750 $ 195 $ 12,945 (1) Other restructuring programs in 2018 include the Vascular Solutions integration program and the EMEA restructuring program (both initiated in 2017) as well as the other 2016 restructuring programs. For a description of these programs, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2017. (2) Other restructuring costs include facility closure, contract termination, and other exit costs. (3) Other restructuring programs in 2017 primarily includes the other 2016 restructuring programs. 2016 Footprint Realignment Plan In 2016, the Company initiated a restructuring plan (the “2016 Footprint realignment plan") involving the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 Footprint realignment plan of between approximately $34 million to $44 million , of which an estimated $27 million to $31 million are expected to result in future cash outlays. Most of these charges, and the related cash outlays, are expected to be made prior to the end of 2018. In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2016 Footprint realignment plan of $1.4 million and $2.1 million for the three months ended April 1, 2018 and April 2, 2017 , respectively, within cost of goods sold. As of April 1, 2018 , the Company has incurred restructuring charges in connection with the 2016 Footprint realignment plan aggregating to $16.8 million . Additionally, as of April 1, 2018 , the Company has incurred restructuring related charges aggregating to $16.1 million related to the 2016 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. The restructuring related charges primarily were included in cost of goods sold. As of April 1, 2018 , the Company has a restructuring reserve of $6.5 million related to this plan, all of which related to termination benefits. 2014 Footprint Realignment Plan In 2014, the Company initiated a restructuring plan (“the 2014 Footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 Footprint realignment plan of approximately $46 million to $51 million , of which an estimated $38 million to $43 million are expected to result in future cash outlays. The Company expects to incur $24 million to $30 million in aggregate capital expenditures under the plan. In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges with respect to the 2014 Footprint realignment plan of $0.4 million and $1.6 million for the three months ended April 1, 2018 and April 2, 2017 respectively, within cost of goods sold. As of April 1, 2018 , the Company has incurred restructuring charges in connection with the 2014 Footprint realignment plan aggregating to $11.9 million . Additionally, as of April 1, 2018 , the Company has incurred restructuring related charges aggregating to $27.3 million related to the 2014 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of April 1, 2018 , the Company has a restructuring reserve of $3.7 million in connection with the plan, all of which related to termination benefits. For additional information regarding the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2017. Restructuring charges by reportable operating segment, and by all other operating segments in the aggregate, for the three months ended April 1, 2018 and April 2, 2017 are set forth in the following table: Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) Vascular North America $ 321 $ 728 Interventional North America 545 4,215 Anesthesia North America 34 247 EMEA 251 7,527 All other 1,912 228 Restructuring charges $ 3,063 $ 12,945

Inventories, net

Inventories, net	3 Months Ended
	Apr. 01, 2018
Inventory Disclosure [Abstract]
Inventories, net	Note 6 — Inventories, net Inventories as of April 1, 2018 and December 31, 2017 consisted of the following: April 1, 2018 December 31, 2017 (Dollars in thousands) Raw materials $ 94,786 $ 98,451 Work-in-process 66,185 62,381 Finished goods 242,705 234,912 Inventories, net $ 403,676 $ 395,744

Goodwill and other intangible a

Goodwill and other intangible assets, net	3 Months Ended
	Apr. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 7 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the three months ended April 1, 2018 : Vascular Interventional North America Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) December 31, 2017 $ 264,869 $ 433,049 $ 157,289 $ 250,912 $ 494,548 $ 209,200 $ 4,883 $ 420,842 $ 2,235,592 Goodwill related to acquisitions — — — — 9 3 — 145 157 Currency translation adjustment — 5,630 303 — 16,225 4,048 — 2,492 28,698 April 1, 2018 $ 264,869 $ 438,679 $ 157,592 $ 250,912 $ 510,782 $ 213,251 $ 4,883 $ 423,479 $ 2,264,447 The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of April 1, 2018 and December 31, 2017 were as follows: Gross Carrying Amount Accumulated Amortization April 1, 2018 December 31, 2017 April 1, 2018 December 31, 2017 (Dollars in thousands) Customer relationships $ 1,044,509 $ 1,023,837 $ (295,480 ) $ (281,263 ) In-process research and development 31,698 34,672 — — Intellectual property 1,312,598 1,287,487 (282,907 ) (258,580 ) Distribution rights 23,922 23,697 (17,490 ) (16,996 ) Trade names 578,646 571,510 (25,990 ) (22,069 ) Non-compete agreements 24,964 23,429 (3,915 ) (1,976 ) $ 3,016,337 $ 2,964,632 $ (625,782 ) $ (580,884 )

Financial instruments

Financial instruments	3 Months Ended
	Apr. 01, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Note 8 — Financial instruments Foreign Currency Forward Contracts The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. For the three months ended April 1, 2018 the Company recognized a gain related to non-designated foreign currency forward contracts of $0.6 million . For the three months ended April 2, 2017 , the Company recognized a loss related to non-designated foreign currency forward contracts of $0.8 million . The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of April 1, 2018 and December 31, 2017 : April 1, 2018 December 31, 2017 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 1,989 $ 914 Non-designated foreign currency forward contracts 198 307 Prepaid expenses and other current assets $ 2,187 $ 1,221 Total asset derivatives $ 2,187 $ 1,221 Liability derivatives: Designated foreign currency forward contracts $ 993 $ 1,373 Non-designated foreign currency forward contracts 455 53 Other current liabilities $ 1,448 $ 1,426 Total liability derivatives $ 1,448 $ 1,426 The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of April 1, 2018 and December 31, 2017 was $117.3 million and $88.5 million , respectively. The total notional amount for all open non-designated foreign currency forward contracts as of April 1, 2018 and December 31, 2017 was $111.5 million and $110.6 million , respectively. All open foreign currency forward contracts as of April 1, 2018 have durations of twelve months or less. There was no ineffectiveness related to the Company’s cash flow hedges during the three months ended April 1, 2018 and April 2, 2017 . Concentration of Credit Risk Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. However, a portion of the Company’s trade accounts receivable outside the United States, include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the creditworthiness of the healthcare systems in those countries and the financial stability of those countries' economies. Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at April 1, 2018 and December 31, 2017 : April 1, 2018 December 31, 2017 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,865 $ 10,255 Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal (2) $ 56,940 $ 49,054 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 16.3 % 14.6 % (1) The current portion of the allowance for doubtful accounts was $3.1 million and $3.5 million as of April 1, 2018 and December 31, 2017 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at April 1, 2018 and December 31, 2017 was $3.7 million and $3.3 million , respectively. For the three months ended April 1, 2018 and April 2, 2017 , net revenues from customers in Greece, Italy, Spain and Portugal were $38.3 million and $31.5 million , respectively.

Fair value measurement

Fair value measurement	3 Months Ended
	Apr. 01, 2018
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017 . The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of April 1, 2018 and December 31, 2017 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,989 $ 8,989 $ — $ — Derivative assets 2,187 — 2,187 — Derivative liabilities 1,448 — 1,448 — Contingent consideration liabilities 281,857 — — 281,857 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,045 $ 9,045 $ — $ — Derivative assets 1,221 — 1,221 — Derivative liabilities 1,426 — 1,426 — Contingent consideration liabilities 272,136 — — 272,136 There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the three months ended April 1, 2018 . Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities as of the measurement date, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. Contingent consideration As of April 1, 2018, the Company estimates that contingent consideration payments will occur in 2018 through 2029, and the maximum amount of undiscounted payments the Company could make under contingent consideration arrangements is $400.4 million . The contingent consideration liabilities, which primarily consist of Company obligations payable if specified net sales goals are achieved, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and project payment dates. The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The contingent consideration liability related to the NeoTract acquisition represents the estimated fair value of the Company's obligations to make payments of up to $375 million in the aggregate if specified sales goals are achieved. Specifically, the payments are based on net sales (as defined in the NeoTract acquisition agreement) for the periods from January 1, 2018 through April 30, 2018 and the years ended December 31, 2018, 2019 and 2020. The fair value of the contingent consideration related to the NeoTract acquisition was estimated using a Monte Carlo valuation approach, which simulates future revenues during the earn out-period using management's best estimates. The Company determines the value of its other contingent consideration liabilities based on a probability-weighted discounted cash flow analysis. Increases in projected revenues and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates may result in significantly lower fair value measurements; decreases in these items may have the opposite effect. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition. Valuation Technique Unobservable Input Range Contingent consideration Monte Carlo simulation Revenue volatility 21.1 % Risk free rate Cost of debt structure Projected year of payment 2018 - 2021 The following table provides information regarding changes, during the three months ended April 1, 2018 , in Level 3 financial liabilities related to contingent consideration: Contingent consideration 2018 (Dollars in thousands) Balance - December 31, 2017 $ 272,136 Payment (91 ) Revaluations 9,592 Translation adjustment 220 Balance - April 1, 2018 $ 281,857

Shareholders' equity

Shareholders' equity	3 Months Ended
	Apr. 01, 2018
Equity [Abstract]
Shareholders' equity	Note 10 — Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended April 1, 2018 April 2, 2017 (Shares in thousands) Basic 45,329 44,893 Dilutive effect of share-based awards 1,044 821 Dilutive effect of convertible notes and warrants 322 901 Diluted 46,695 46,615 In connection with the issuance by the Company in 2010 of convertible notes that matured in August 2017, and as part of hedging arrangements between the Company and two institutional counterparties, the Company issued warrants to the counterparties, entitling them to purchase Company common stock. These transactions are described in greater detail in Note 11 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. At April 1, 2018, warrants to purchase 374,418 shares at an exercise price of $74.65 per share remained outstanding. The remaining warrants expire ratably over a period ending on August 31, 2018. At April 1, 2018, the intrinsic value of the warrants (i.e. the excess of the aggregate market price of the underlying shares over the aggregate exercise price of the warrants) was $67.5 million . The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.6 million and 0.5 million for the three months ended April 1, 2018 and April 2, 2017 , respectively. The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the three months ended April 1, 2018 and April 2, 2017 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808 ) $ (126,623 ) $ (265,091 ) Other comprehensive income (loss) before reclassifications 1,341 (478 ) 81,188 82,051 Amounts reclassified from accumulated other comprehensive income (720 ) 1,359 — 639 Net current-period other comprehensive income 621 881 81,188 82,690 Balance as of April 1, 2018 $ 961 $ (137,927 ) $ (45,435 ) $ (182,401 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive (loss) before reclassifications 350 (241 ) 46,982 47,091 Amounts reclassified from accumulated other comprehensive loss 1,378 1,131 — 2,509 Net current-period other comprehensive income 1,728 890 46,982 49,600 Balance at April 2, 2017 $ (696 ) $ (135,706 ) $ (252,715 ) $ (389,117 ) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (833 ) $ 1,645 Total before tax (833 ) 1,645 Taxes (benefit) 113 (267 ) Net of tax $ (720 ) $ 1,378 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,746 $ 1,726 Prior-service costs (1) 24 29 Total before tax 1,770 1,755 Tax benefit (411 ) (624 ) Net of tax $ 1,359 $ 1,131 Total reclassifications, net of tax $ 639 $ 2,509 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continuing

Taxes on income from continuing operations	3 Months Ended
	Apr. 01, 2018
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Note 11 — Taxes on income from continuing operations Three Months Ended April 1, 2018 April 2, 2017 Effective income tax rate 10.2% (7.1)% The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The legislation significantly changes U.S. tax law by, among other things, permanently reducing corporate income tax rates from a maximum of 35% to 21%, effective January 1, 2018; implementing a territorial tax system, by generally providing for, among other things, a dividends received deduction on the foreign source portion of dividends received from a foreign corporation if specified conditions are met; imposing two new U.S. base erosion provisions: (1) the global intangible low-taxed income ("GILTI") provisions and (2) the base erosion and anti-abuse tax ("BEAT") provisions; and imposing a one-time repatriation tax on undistributed post-1986 foreign subsidiary earnings and profits, which are deemed repatriated for purposes of the tax. In accordance with the applicable provisions of SEC Staff Accounting Bulletin No. 118, the Company included in its consolidated financial statements as of December 31, 2017 provisional amounts reflecting the tax impact related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities. Once the Company's accounting for the income tax effects of the TCJA is complete, the amounts with respect to the income tax effects of the TCJA may differ from the provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the TCJA. The effective income tax rate for the three months ended April 1, 2018 and April 2, 2017 was 10.2% and (7.1)% , respectively. The effective income tax rate for the three months ended April 1, 2018 includes the benefit of a lower U.S. corporate income tax rate of 21.0% from the enactment of the TCJA, partially offset by a tax cost associated with GILTI and other TCJA related changes. The effective income tax rate for the three months ended April 2, 2017 reflects a tax benefit associated with costs incurred in connection with the Vascular Solutions acquisition.

Pension and other postretiremen

Pension and other postretirement benefits	3 Months Ended
	Apr. 01, 2018
Compensation and Retirement Disclosure [Abstract]
Pension and other postretirement benefits	Note 12 — Pension and other postretirement benefits The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of April 1, 2018 , no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 (Dollars in thousands) Service cost $ 378 $ 717 $ 52 $ 74 Interest cost 3,722 3,785 378 378 Expected return on plan assets (7,421 ) (6,743 ) — — Net amortization and deferral 1,707 1,690 62 65 Net benefits expense (income) $ (1,614 ) $ (551 ) $ 492 $ 517

Commitments and contingent liab

Commitments and contingent liabilities	3 Months Ended
	Apr. 01, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Note 13 — Commitments and contingent liabilities Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At April 1, 2018 , the Company has recorded $1.0 million and $5.7 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of April 1, 2018 . The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15 - 20 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment, environmental and other matters. As of April 1, 2018 , the Company has recorded accrued liabilities of $1.8 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of April 1, 2018 , the most significant tax examinations in process are in Germany, Italy, and the United States. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts the reserves to address developments with respect to its uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results. Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Segment information

Segment information	3 Months Ended
	Apr. 01, 2018
Segment Reporting [Abstract]
Segment information	Note 14 — Segment information Following the Company's acquisition of Vascular Solutions, the Company commenced an integration program under which it is combining the Vascular Solutions' business with some of its legacy businesses. As a result, effective during the fourth quarter 2017, the Company realigned its operating segments. The changes to the operating segments were also made to reflect the manner in which the Company’s chief operating decision maker assesses business performance and allocates resources. The Company now has the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, the Company will continue to present certain operating segments, which currently include the Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because they are not material. All prior comparative periods presented have been restated to reflect these changes. The following tables present the Company’s segment results for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) Vascular North America $ 83,048 $ 79,011 Interventional North America 60,196 39,946 Anesthesia North America 50,565 48,207 Surgical North America 40,677 45,944 EMEA 159,870 133,574 Asia 58,244 50,168 OEM 45,854 43,346 All other 88,776 47,685 Net revenues $ 587,230 $ 487,881 Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) Vascular North America $ 24,662 $ 18,290 Interventional North America 14,120 (8,035 ) Anesthesia North America 17,333 13,304 Surgical North America 14,748 16,380 EMEA 31,770 21,310 Asia 13,368 10,884 OEM 9,016 9,121 All other (11,973 ) 9,327 Total segment operating profit (1) 113,044 90,581 Unallocated expenses (2) (26,201 ) (29,762 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 86,843 $ 60,819 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets. The following table provides total net revenues by geographic region (based on the Company's selling location) for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) United States $ 344,357 $ 286,314 Europe 171,320 141,022 Asia 49,555 43,004 All other 21,998 17,541 Net revenues $ 587,230 $ 487,881

Condensed consolidating guarant

Condensed consolidating guarantor financial information	3 Months Ended
	Apr. 01, 2018
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Condensed consolidating guarantor financial information The Company’s $250 million principal amount of 5.25% Senior Notes due 2024 (the “2024 Notes”), $400 million principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”) and $500 million principal amount of 4.625% Senior Notes due 2027 (the “2027 Notes," and collectively with the 2024 Notes and the 2026 Notes, the "Senior Notes") are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The 2024 Notes, 2026 Notes and 2027 Notes are guaranteed by the same Guarantor Subsidiaries. The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three months ended April 1, 2018 and April 2, 2017 , condensed consolidating balance sheets as of April 1, 2018 and December 31, 2017 and condensed consolidating statements of cash flows for the three months ended April 1, 2018 and April 2, 2017 , provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes), on a combined basis; and d. Parent Company and its subsidiaries on a consolidated basis. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. During the first quarter 2018, a Guarantor Subsidiary merged with and into Parent; the transaction was reflected as of the beginning of the earliest period presented in the condensed consolidating financial statements. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended April 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 379,419 $ 320,009 $ (112,198 ) $ 587,230 Cost of goods sold — 217,604 142,008 (103,652 ) 255,960 Gross profit — 161,815 178,001 (8,546 ) 331,270 Selling, general and administrative expenses 9,181 130,914 75,771 (529 ) 215,337 Research and development expenses 227 19,368 6,432 — 26,027 Restructuring charges — 908 2,155 — 3,063 (Loss) income from continuing operations before interest and taxes (9,408 ) 10,625 93,643 (8,017 ) 86,843 Interest, net 22,141 2,931 598 — 25,670 (Loss) income from continuing operations before taxes (31,549 ) 7,694 93,045 (8,017 ) 61,173 (Benefit) taxes on (loss) income from continuing operations (13,192 ) 6,423 14,177 (1,166 ) 6,242 Equity in net income of consolidated subsidiaries 74,567 76,876 293 (151,736 ) — Income from continuing operations 56,210 78,147 79,161 (158,587 ) 54,931 Operating (loss) income from discontinued operations (44 ) — 1,279 — 1,235 Tax benefit on loss from discontinued operations (18 ) — — — (18 ) (Loss) income from discontinued operations (26 ) — 1,279 — 1,253 Net income 56,184 78,147 80,440 (158,587 ) 56,184 Other comprehensive income 82,690 70,119 87,227 (157,346 ) 82,690 Comprehensive income $ 138,874 $ 148,266 $ 167,667 $ (315,933 ) $ 138,874 Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 315,643 $ 276,315 $ (104,077 ) $ 487,881 Cost of goods sold — 192,001 143,896 (103,576 ) 232,321 Gross profit — 123,642 132,419 (501 ) 255,560 Selling, general and administrative expenses 20,519 94,043 48,844 563 163,969 Research and development expenses 235 11,186 6,406 — 17,827 Restructuring charges — 5,374 7,571 — 12,945 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (20,754 ) 13,039 69,598 (1,064 ) 60,819 Interest, net 24,273 (7,562 ) 846 — 17,557 Loss on extinguishment of debt 5,582 — — — 5,582 (Loss) income from continuing operations before taxes (50,609 ) 20,601 68,752 (1,064 ) 37,680 (Benefit) taxes on (loss) income from continuing operations (21,333 ) 5,911 12,229 524 (2,669 ) Equity in net income of consolidated subsidiaries 69,625 55,802 216 (125,643 ) — Income from continuing operations 40,349 70,492 56,739 (127,231 ) 40,349 Operating loss from discontinued operations (282 ) — — — (282 ) Tax benefit on loss from discontinued operations (103 ) — — — (103 ) Loss from discontinued operations (179 ) — — — (179 ) Net income 40,170 70,492 56,739 (127,231 ) 40,170 Other comprehensive income 49,600 49,404 53,901 (103,305 ) 49,600 Comprehensive income $ 89,770 $ 119,896 $ 110,640 $ (230,536 ) $ 89,770 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS April 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 28,407 $ 10,200 $ 340,265 $ — $ 378,872 Accounts receivable, net 2,822 35,826 315,300 5,192 359,140 Accounts receivable from consolidated subsidiaries 25,239 994,384 346,925 (1,366,548 ) — Inventories, net — 246,289 192,343 (34,956 ) 403,676 Prepaid expenses and other current assets 15,470 12,482 21,064 3,982 52,998 Prepaid taxes — — 7,234 — 7,234 Assets held for sale — 3,239 — — 3,239 Total current assets 71,938 1,302,420 1,223,131 (1,392,330 ) 1,205,159 Property, plant and equipment, net 2,340 205,115 182,064 — 389,519 Goodwill — 1,247,150 1,017,297 — 2,264,447 Intangibles assets, net — 1,333,983 1,056,572 — 2,390,555 Investments in consolidated subsidiaries 5,963,828 1,827,988 19,723 (7,811,539 ) — Deferred tax assets — — 6,230 (2,261 ) 3,969 Notes receivable and other amounts due from consolidated subsidiaries 2,171,364 2,189,631 — (4,360,995 ) — Other assets 30,864 6,426 9,661 — 46,951 Total assets $ 8,240,334 $ 8,112,713 $ 3,514,678 $ (13,567,125 ) $ 6,300,600 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 27,500 $ — $ 50,000 $ — $ 77,500 Accounts payable 2,954 45,416 36,316 — 84,686 Accounts payable to consolidated subsidiaries 1,014,612 275,625 76,311 (1,366,548 ) — Accrued expenses 20,314 33,152 47,662 — 101,128 Current portion of contingent consideration — 162,061 — — 162,061 Payroll and benefit-related liabilities 15,618 24,212 40,588 — 80,418 Accrued interest 20,463 — 40 — 20,503 Income taxes payable 936 — 13,730 (1,166 ) 13,500 Other current liabilities 1,466 5,355 5,157 — 11,978 Total current liabilities 1,103,863 545,821 269,804 (1,367,714 ) 551,774 Long-term borrowings 2,154,217 — — — 2,154,217 Deferred tax liabilities 88,632 270,305 260,035 (2,261 ) 616,711 Pension and postretirement benefit liabilities 66,986 32,393 18,495 — 117,874 Noncurrent liability for uncertain tax positions 1,396 8,237 2,995 — 12,628 Notes payable and other amounts due to consolidated subsidiaries 2,114,287 2,048,841 197,867 (4,360,995 ) — Noncurrent contingent consideration — 108,727 11,069 — 119,796 Other liabilities 150,453 5,802 10,845 — 167,100 Total liabilities 5,679,834 3,020,126 771,110 (5,730,970 ) 3,740,100 Total shareholders' equity 2,560,500 5,092,587 2,743,568 (7,836,155 ) 2,560,500 Total liabilities and shareholders' equity $ 8,240,334 $ 8,112,713 $ 3,514,678 $ (13,567,125 ) $ 6,300,600 December 31, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 37,803 $ 8,933 $ 286,822 $ — $ 333,558 Accounts receivable, net 2,414 57,818 280,980 4,663 345,875 Accounts receivable from consolidated subsidiaries 14,478 1,177,246 343,115 (1,534,839 ) — Inventories, net — 245,533 176,490 (26,279 ) 395,744 Prepaid expenses and other current assets 14,874 9,236 19,790 3,982 47,882 Prepaid taxes — — 5,748 — 5,748 Total current assets 69,569 1,498,766 1,112,945 (1,552,473 ) 1,128,807 Property, plant and equipment, net 2,088 213,663 167,248 — 382,999 Goodwill — 1,246,144 989,448 — 2,235,592 Intangibles assets, net — 1,355,275 1,028,473 — 2,383,748 Investments in consolidated subsidiaries 5,806,244 1,674,077 19,620 (7,499,941 ) — Deferred tax assets — — 6,071 (2,261 ) 3,810 Notes receivable and other amounts due from consolidated subsidiaries 2,452,101 2,231,832 — (4,683,933 ) — Other assets 31,173 6,397 8,966 — 46,536 Total assets $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 4,269 46,992 40,766 — 92,027 Accounts payable to consolidated subsidiaries 1,211,568 261,121 62,150 (1,534,839 ) — Accrued expenses 17,957 31,827 47,069 — 96,853 Current portion of contingent consideration — 74,224 — — 74,224 Payroll and benefit-related liabilities 21,145 44,009 42,261 — 107,415 Accrued interest 6,133 — 32 — 6,165 Income taxes payable 4,352 — 7,162 — 11,514 Other current liabilities 1,461 3,775 3,817 — 9,053 Total current liabilities 1,303,510 461,948 253,257 (1,534,839 ) 483,876 Long-term borrowings 2,162,927 — — — 2,162,927 Deferred tax liabilities 88,512 265,426 251,999 (2,261 ) 603,676 Pension and postretirement benefit liabilities 70,860 32,750 17,800 — 121,410 Noncurrent liability for uncertain tax positions 1,117 8,196 2,983 — 12,296 Notes payable and other amounts due to consolidated subsidiaries 2,155,146 2,320,611 208,176 (4,683,933 ) — Noncurrent contingent consideration — 186,923 10,989 — 197,912 Other liabilities 148,572 7,850 12,442 — 168,864 Total liabilities 5,930,644 3,283,704 757,646 (6,221,033 ) 3,750,961 Total shareholders' equity 2,430,531 4,942,450 2,575,125 (7,517,575 ) 2,430,531 Total liabilities and shareholders' equity $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Three Months Ended April 1, 2018 Parent Guarantor Non-Guarantor Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (108,377 ) $ 134,198 $ 61,027 $ 86,848 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (159 ) (5,015 ) (10,573 ) (15,747 ) Payments for businesses and intangibles acquired, net of cash acquired — — (3,684 ) (3,684 ) Net cash used in investing activities from continuing operations (159 ) (5,015 ) (14,257 ) (19,431 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (18,500 ) — — (18,500 ) Debt extinguishment, issuance and amendment fees (74 ) — — (74 ) Net proceeds from share based compensation plans and the related tax impacts 1,400 — — 1,400 Payments for contingent consideration — (91 ) — (91 ) Dividends paid (15,447 ) — — (15,447 ) Intercompany transactions 131,967 (127,825 ) (4,142 ) — Net cash provided by (used in) financing activities from continuing operations 99,346 (127,916 ) (4,142 ) (32,712 ) Cash flows from discontinued operations: Net cash used in operating activities (206 ) — — (206 ) Net cash used in discontinued operations (206 ) — — (206 ) Effect of exchange rate changes on cash and cash equivalents — — 10,815 10,815 Net (decrease) increase in cash and cash equivalents (9,396 ) 1,267 53,443 45,314 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 333,558 Cash and cash equivalents at the end of the period $ 28,407 $ 10,200 $ 340,265 $ 378,872 Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (86,020 ) $ 158,343 $ 80,535 $ (61,918 ) $ 90,940 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (155 ) (2,206 ) (10,533 ) — (12,894 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — — — (975,524 ) Net cash used in investing activities from continuing operations (975,679 ) (2,206 ) (4,201 ) — (982,086 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (138,251 ) — — — (138,251 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts (505 ) — — — (505 ) Payments for contingent consideration — (79 ) — — (79 ) Dividends paid (15,287 ) — — — (15,287 ) Intercompany transactions 179,151 (149,496 ) (29,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,200,494 (149,575 ) (91,573 ) 61,918 1,021,264 Cash flows from discontinued operations: Net cash used in operating activities (266 ) — — — (266 ) Net cash used in discontinued operations (266 ) — — — (266 ) Effect of exchange rate changes on cash and cash equivalents — — 15,488 — 15,488 Net increase in cash and cash equivalents 138,529 6,562 249 — 145,340 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 153,100 $ 7,593 $ 528,436 $ — $ 689,129

Subsequent events (Notes)

Subsequent events (Notes)	3 Months Ended
	Apr. 01, 2018
Subsequent Events [Abstract]
Subsequent events	Subsequent event On May 1, 2018, the Company initiated a restructuring plan involving the relocation of certain manufacturing operations to an existing lower-cost location, the outsourcing of certain of the Company’s distribution operations, and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to commence in the second quarter 2018 and are expected to be substantially completed by the end of 2024. The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $60 million to $70 million Other exit costs (1) $2 million to $4 million Restructuring charges $62 million to $74 million Restructuring related charges (2) $40 million to $59 million Total restructuring and restructuring related charges $102 million to $133 million (1) Includes contract termination costs as well as facility closure and other exit costs (employee relocation costs, equipment relocation costs and outplacement). (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new location, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold. The Company estimates $99 million to $127 million of the restructuring and restructuring related charges will result in future cash outlays. Additionally, the Company expects that it will incur $19 million to $23 million in aggregate capital expenditures under the plan. The Company expects to incur most of these charges and cash outlays prior to 2024. As the 2018 Footprint realignment plan progresses, management will reevaluate the estimated expenses and charges set forth above, and may revise its estimates, as appropriate, consistent with GAAP.

New accounting standards (Polic

New accounting standards (Policies)	3 Months Ended
	Apr. 01, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. The Company adopted the new standard on January 1, 2018 using the modified retrospective method applied to all contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $0.3 million increase to the Company's opening balance of retained earnings on the adoption date. Also in connection with the adoption of the new standard, the Company reclassified the reserve for product returns from a contra-receivable to a liability. The reserve for returns and allowances was $4.4 million at April 1, 2018. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018 using the modified retrospective method of adoption; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings on the adoption date. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated results of operations and financial position. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits for a reclassification of these amounts to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted for reporting periods for which financial statements have not yet been issued. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues (Tables)

Net revenues (Tables)	3 Months Ended
	Apr. 01, 2018
Deferred Revenue Disclosure [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table disaggregates revenue by global product category for the three months ended April 1, 2018 and April 2, 2017. Three Months Ended April 1, 2018 April 2, 2017 Revenue by global product category (1) (2) (Dollars in thousands) Vascular access $ 144,241 $ 130,022 Anesthesia 85,418 81,205 Interventional 71,680 43,966 Surgical 85,632 87,304 Interventional urology 42,300 — OEM 45,872 43,346 Other (3) 112,087 102,038 Net revenues $ 587,230 $ 487,881 (1) The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined based on the particular products sold by the segments, and its non-North American reportable segments are defined based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above. (2) Products included within certain of the product categories listed in the table above differ from those included within the similarly named reportable segment. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which those sales originated, while the classification of products within the product categories listed above includes sales originating from multiple call points within the customer's organization. (3) Other revenues in the table above comprise the Company’s respiratory, urology and cardiac product categories.

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Apr. 01, 2018
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information	The following unaudited pro forma combined financial information for the three months ended April 2, 2017 gives effect to the Vascular Solutions and NeoTract acquisitions as if they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended April 2, 2017 (Dollars and shares in thousands, except per share) Net revenue $ 533,318 Net income $ 37,108 Basic earnings per common share: Net income $ 0.83 Diluted earnings per common share: Net income $ 0.80 Weighted average common shares outstanding: Basic 44,893 Diluted 46,615

Restructuring (credits) charg28

Restructuring (credits) charges (Tables)	3 Months Ended
	Apr. 01, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Other Impairment Charges	Restructuring charges by reportable operating segment, and by all other operating segments in the aggregate, for the three months ended April 1, 2018 and April 2, 2017 are set forth in the following table: Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) Vascular North America $ 321 $ 728 Interventional North America 545 4,215 Anesthesia North America 34 247 EMEA 251 7,527 All other 1,912 228 Restructuring charges $ 3,063 $ 12,945 The following tables provide information regarding restructuring charges recognized by the Company for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 Termination benefits Other restructuring costs (2) Total (Dollars in thousands) 2016 Footprint realignment plan $ 1,955 $ 194 $ 2,149 2014 Footprint realignment plan 116 8 124 Other restructuring programs (1) 585 205 790 Restructuring charges $ 2,656 $ 407 $ 3,063 Three Months Ended April 2, 2017 Termination benefits Other restructuring costs (2) Total (Dollars in thousands) Vascular Solutions Integration Program $ 4,482 $ — $ 4,482 EMEA Restructuring Program 7,121 — 7,121 2016 Footprint realignment plan 539 (30 ) 509 2014 Footprint realignment plan 303 8 311 Other restructuring programs (3) 305 217 522 Restructuring charges $ 12,750 $ 195 $ 12,945 (1) Other restructuring programs in 2018 include the Vascular Solutions integration program and the EMEA restructuring program (both initiated in 2017) as well as the other 2016 restructuring programs. For a description of these programs, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2017. (2) Other restructuring costs include facility closure, contract termination, and other exit costs. (3) Other restructuring programs in 2017 primarily includes the other 2016 restructuring programs.

Inventories, net (Tables)

Inventories, net (Tables)	3 Months Ended
	Apr. 01, 2018
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of April 1, 2018 and December 31, 2017 consisted of the following: April 1, 2018 December 31, 2017 (Dollars in thousands) Raw materials $ 94,786 $ 98,451 Work-in-process 66,185 62,381 Finished goods 242,705 234,912 Inventories, net $ 403,676 $ 395,744

Goodwill and other intangible30

Goodwill and other intangible assets, net (Tables)	3 Months Ended
	Apr. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the three months ended April 1, 2018 : Vascular Interventional North America Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) December 31, 2017 $ 264,869 $ 433,049 $ 157,289 $ 250,912 $ 494,548 $ 209,200 $ 4,883 $ 420,842 $ 2,235,592 Goodwill related to acquisitions — — — — 9 3 — 145 157 Currency translation adjustment — 5,630 303 — 16,225 4,048 — 2,492 28,698 April 1, 2018 $ 264,869 $ 438,679 $ 157,592 $ 250,912 $ 510,782 $ 213,251 $ 4,883 $ 423,479 $ 2,264,447
Schedule of Finite-Lived Intangible Assets	The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of April 1, 2018 and December 31, 2017 were as follows: Gross Carrying Amount Accumulated Amortization April 1, 2018 December 31, 2017 April 1, 2018 December 31, 2017 (Dollars in thousands) Customer relationships $ 1,044,509 $ 1,023,837 $ (295,480 ) $ (281,263 ) In-process research and development 31,698 34,672 — — Intellectual property 1,312,598 1,287,487 (282,907 ) (258,580 ) Distribution rights 23,922 23,697 (17,490 ) (16,996 ) Trade names 578,646 571,510 (25,990 ) (22,069 ) Non-compete agreements 24,964 23,429 (3,915 ) (1,976 ) $ 3,016,337 $ 2,964,632 $ (625,782 ) $ (580,884 )

Financial instruments (Tables)

Financial instruments (Tables)	3 Months Ended
	Apr. 01, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of April 1, 2018 and December 31, 2017 : April 1, 2018 December 31, 2017 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 1,989 $ 914 Non-designated foreign currency forward contracts 198 307 Prepaid expenses and other current assets $ 2,187 $ 1,221 Total asset derivatives $ 2,187 $ 1,221 Liability derivatives: Designated foreign currency forward contracts $ 993 $ 1,373 Non-designated foreign currency forward contracts 455 53 Other current liabilities $ 1,448 $ 1,426 Total liability derivatives $ 1,448 $ 1,426
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at April 1, 2018 and December 31, 2017 : April 1, 2018 December 31, 2017 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,865 $ 10,255 Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal (2) $ 56,940 $ 49,054 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 16.3 % 14.6 % (1) The current portion of the allowance for doubtful accounts was $3.1 million and $3.5 million as of April 1, 2018 and December 31, 2017 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at April 1, 2018 and December 31, 2017 was $3.7 million and $3.3 million , respectively.

Fair value measurement (Tables)

Fair value measurement (Tables)	3 Months Ended
	Apr. 01, 2018
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of April 1, 2018 and December 31, 2017 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,989 $ 8,989 $ — $ — Derivative assets 2,187 — 2,187 — Derivative liabilities 1,448 — 1,448 — Contingent consideration liabilities 281,857 — — 281,857 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,045 $ 9,045 $ — $ — Derivative assets 1,221 — 1,221 — Derivative liabilities 1,426 — 1,426 — Contingent consideration liabilities 272,136 — — 272,136
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes, during the three months ended April 1, 2018 , in Level 3 financial liabilities related to contingent consideration: Contingent consideration 2018 (Dollars in thousands) Balance - December 31, 2017 $ 272,136 Payment (91 ) Revaluations 9,592 Translation adjustment 220 Balance - April 1, 2018 $ 281,857
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition. Valuation Technique Unobservable Input Range Contingent consideration Monte Carlo simulation Revenue volatility 21.1 % Risk free rate Cost of debt structure Projected year of payment 2018 - 2021

Shareholders' equity (Tables)

Shareholders' equity (Tables)	3 Months Ended
	Apr. 01, 2018
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended April 1, 2018 April 2, 2017 (Shares in thousands) Basic 45,329 44,893 Dilutive effect of share-based awards 1,044 821 Dilutive effect of convertible notes and warrants 322 901 Diluted 46,695 46,615
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the three months ended April 1, 2018 and April 2, 2017 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808 ) $ (126,623 ) $ (265,091 ) Other comprehensive income (loss) before reclassifications 1,341 (478 ) 81,188 82,051 Amounts reclassified from accumulated other comprehensive income (720 ) 1,359 — 639 Net current-period other comprehensive income 621 881 81,188 82,690 Balance as of April 1, 2018 $ 961 $ (137,927 ) $ (45,435 ) $ (182,401 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive (loss) before reclassifications 350 (241 ) 46,982 47,091 Amounts reclassified from accumulated other comprehensive loss 1,378 1,131 — 2,509 Net current-period other comprehensive income 1,728 890 46,982 49,600 Balance at April 2, 2017 $ (696 ) $ (135,706 ) $ (252,715 ) $ (389,117 )
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (833 ) $ 1,645 Total before tax (833 ) 1,645 Taxes (benefit) 113 (267 ) Net of tax $ (720 ) $ 1,378 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,746 $ 1,726 Prior-service costs (1) 24 29 Total before tax 1,770 1,755 Tax benefit (411 ) (624 ) Net of tax $ 1,359 $ 1,131 Total reclassifications, net of tax $ 639 $ 2,509 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui34

Taxes on income from continuing operations (Tables)	3 Months Ended
	Apr. 01, 2018
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	Three Months Ended April 1, 2018 April 2, 2017 Effective income tax rate 10.2% (7.1)%

Pension and other postretirem35

Pension and other postretirement benefits (Tables)	3 Months Ended
	Apr. 01, 2018
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Benefit Cost of Pension and Postretirement Benefit Plans	Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 (Dollars in thousands) Service cost $ 378 $ 717 $ 52 $ 74 Interest cost 3,722 3,785 378 378 Expected return on plan assets (7,421 ) (6,743 ) — — Net amortization and deferral 1,707 1,690 62 65 Net benefits expense (income) $ (1,614 ) $ (551 ) $ 492 $ 517

Segment information (Tables)

Segment information (Tables)	3 Months Ended
	Apr. 01, 2018
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) Vascular North America $ 83,048 $ 79,011 Interventional North America 60,196 39,946 Anesthesia North America 50,565 48,207 Surgical North America 40,677 45,944 EMEA 159,870 133,574 Asia 58,244 50,168 OEM 45,854 43,346 All other 88,776 47,685 Net revenues $ 587,230 $ 487,881 Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) Vascular North America $ 24,662 $ 18,290 Interventional North America 14,120 (8,035 ) Anesthesia North America 17,333 13,304 Surgical North America 14,748 16,380 EMEA 31,770 21,310 Asia 13,368 10,884 OEM 9,016 9,121 All other (11,973 ) 9,327 Total segment operating profit (1) 113,044 90,581 Unallocated expenses (2) (26,201 ) (29,762 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 86,843 $ 60,819 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.
Schedule Of Revenues And Property Plant Equipment By Geographic Region Table	The following table provides total net revenues by geographic region (based on the Company's selling location) for the three months ended April 1, 2018 and April 2, 2017 : Three Months Ended April 1, 2018 April 2, 2017 (Dollars in thousands) United States $ 344,357 $ 286,314 Europe 171,320 141,022 Asia 49,555 43,004 All other 21,998 17,541 Net revenues $ 587,230 $ 487,881

Condensed consolidating guara37

Condensed consolidating guarantor financial information (Tables)	3 Months Ended
	Apr. 01, 2018
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended April 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 379,419 $ 320,009 $ (112,198 ) $ 587,230 Cost of goods sold — 217,604 142,008 (103,652 ) 255,960 Gross profit — 161,815 178,001 (8,546 ) 331,270 Selling, general and administrative expenses 9,181 130,914 75,771 (529 ) 215,337 Research and development expenses 227 19,368 6,432 — 26,027 Restructuring charges — 908 2,155 — 3,063 (Loss) income from continuing operations before interest and taxes (9,408 ) 10,625 93,643 (8,017 ) 86,843 Interest, net 22,141 2,931 598 — 25,670 (Loss) income from continuing operations before taxes (31,549 ) 7,694 93,045 (8,017 ) 61,173 (Benefit) taxes on (loss) income from continuing operations (13,192 ) 6,423 14,177 (1,166 ) 6,242 Equity in net income of consolidated subsidiaries 74,567 76,876 293 (151,736 ) — Income from continuing operations 56,210 78,147 79,161 (158,587 ) 54,931 Operating (loss) income from discontinued operations (44 ) — 1,279 — 1,235 Tax benefit on loss from discontinued operations (18 ) — — — (18 ) (Loss) income from discontinued operations (26 ) — 1,279 — 1,253 Net income 56,184 78,147 80,440 (158,587 ) 56,184 Other comprehensive income 82,690 70,119 87,227 (157,346 ) 82,690 Comprehensive income $ 138,874 $ 148,266 $ 167,667 $ (315,933 ) $ 138,874 Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 315,643 $ 276,315 $ (104,077 ) $ 487,881 Cost of goods sold — 192,001 143,896 (103,576 ) 232,321 Gross profit — 123,642 132,419 (501 ) 255,560 Selling, general and administrative expenses 20,519 94,043 48,844 563 163,969 Research and development expenses 235 11,186 6,406 — 17,827 Restructuring charges — 5,374 7,571 — 12,945 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (20,754 ) 13,039 69,598 (1,064 ) 60,819 Interest, net 24,273 (7,562 ) 846 — 17,557 Loss on extinguishment of debt 5,582 — — — 5,582 (Loss) income from continuing operations before taxes (50,609 ) 20,601 68,752 (1,064 ) 37,680 (Benefit) taxes on (loss) income from continuing operations (21,333 ) 5,911 12,229 524 (2,669 ) Equity in net income of consolidated subsidiaries 69,625 55,802 216 (125,643 ) — Income from continuing operations 40,349 70,492 56,739 (127,231 ) 40,349 Operating loss from discontinued operations (282 ) — — — (282 ) Tax benefit on loss from discontinued operations (103 ) — — — (103 ) Loss from discontinued operations (179 ) — — — (179 ) Net income 40,170 70,492 56,739 (127,231 ) 40,170 Other comprehensive income 49,600 49,404 53,901 (103,305 ) 49,600 Comprehensive income $ 89,770 $ 119,896 $ 110,640 $ (230,536 ) $ 89,770
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS April 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 28,407 $ 10,200 $ 340,265 $ — $ 378,872 Accounts receivable, net 2,822 35,826 315,300 5,192 359,140 Accounts receivable from consolidated subsidiaries 25,239 994,384 346,925 (1,366,548 ) — Inventories, net — 246,289 192,343 (34,956 ) 403,676 Prepaid expenses and other current assets 15,470 12,482 21,064 3,982 52,998 Prepaid taxes — — 7,234 — 7,234 Assets held for sale — 3,239 — — 3,239 Total current assets 71,938 1,302,420 1,223,131 (1,392,330 ) 1,205,159 Property, plant and equipment, net 2,340 205,115 182,064 — 389,519 Goodwill — 1,247,150 1,017,297 — 2,264,447 Intangibles assets, net — 1,333,983 1,056,572 — 2,390,555 Investments in consolidated subsidiaries 5,963,828 1,827,988 19,723 (7,811,539 ) — Deferred tax assets — — 6,230 (2,261 ) 3,969 Notes receivable and other amounts due from consolidated subsidiaries 2,171,364 2,189,631 — (4,360,995 ) — Other assets 30,864 6,426 9,661 — 46,951 Total assets $ 8,240,334 $ 8,112,713 $ 3,514,678 $ (13,567,125 ) $ 6,300,600 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 27,500 $ — $ 50,000 $ — $ 77,500 Accounts payable 2,954 45,416 36,316 — 84,686 Accounts payable to consolidated subsidiaries 1,014,612 275,625 76,311 (1,366,548 ) — Accrued expenses 20,314 33,152 47,662 — 101,128 Current portion of contingent consideration — 162,061 — — 162,061 Payroll and benefit-related liabilities 15,618 24,212 40,588 — 80,418 Accrued interest 20,463 — 40 — 20,503 Income taxes payable 936 — 13,730 (1,166 ) 13,500 Other current liabilities 1,466 5,355 5,157 — 11,978 Total current liabilities 1,103,863 545,821 269,804 (1,367,714 ) 551,774 Long-term borrowings 2,154,217 — — — 2,154,217 Deferred tax liabilities 88,632 270,305 260,035 (2,261 ) 616,711 Pension and postretirement benefit liabilities 66,986 32,393 18,495 — 117,874 Noncurrent liability for uncertain tax positions 1,396 8,237 2,995 — 12,628 Notes payable and other amounts due to consolidated subsidiaries 2,114,287 2,048,841 197,867 (4,360,995 ) — Noncurrent contingent consideration — 108,727 11,069 — 119,796 Other liabilities 150,453 5,802 10,845 — 167,100 Total liabilities 5,679,834 3,020,126 771,110 (5,730,970 ) 3,740,100 Total shareholders' equity 2,560,500 5,092,587 2,743,568 (7,836,155 ) 2,560,500 Total liabilities and shareholders' equity $ 8,240,334 $ 8,112,713 $ 3,514,678 $ (13,567,125 ) $ 6,300,600 December 31, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 37,803 $ 8,933 $ 286,822 $ — $ 333,558 Accounts receivable, net 2,414 57,818 280,980 4,663 345,875 Accounts receivable from consolidated subsidiaries 14,478 1,177,246 343,115 (1,534,839 ) — Inventories, net — 245,533 176,490 (26,279 ) 395,744 Prepaid expenses and other current assets 14,874 9,236 19,790 3,982 47,882 Prepaid taxes — — 5,748 — 5,748 Total current assets 69,569 1,498,766 1,112,945 (1,552,473 ) 1,128,807 Property, plant and equipment, net 2,088 213,663 167,248 — 382,999 Goodwill — 1,246,144 989,448 — 2,235,592 Intangibles assets, net — 1,355,275 1,028,473 — 2,383,748 Investments in consolidated subsidiaries 5,806,244 1,674,077 19,620 (7,499,941 ) — Deferred tax assets — — 6,071 (2,261 ) 3,810 Notes receivable and other amounts due from consolidated subsidiaries 2,452,101 2,231,832 — (4,683,933 ) — Other assets 31,173 6,397 8,966 — 46,536 Total assets $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 4,269 46,992 40,766 — 92,027 Accounts payable to consolidated subsidiaries 1,211,568 261,121 62,150 (1,534,839 ) — Accrued expenses 17,957 31,827 47,069 — 96,853 Current portion of contingent consideration — 74,224 — — 74,224 Payroll and benefit-related liabilities 21,145 44,009 42,261 — 107,415 Accrued interest 6,133 — 32 — 6,165 Income taxes payable 4,352 — 7,162 — 11,514 Other current liabilities 1,461 3,775 3,817 — 9,053 Total current liabilities 1,303,510 461,948 253,257 (1,534,839 ) 483,876 Long-term borrowings 2,162,927 — — — 2,162,927 Deferred tax liabilities 88,512 265,426 251,999 (2,261 ) 603,676 Pension and postretirement benefit liabilities 70,860 32,750 17,800 — 121,410 Noncurrent liability for uncertain tax positions 1,117 8,196 2,983 — 12,296 Notes payable and other amounts due to consolidated subsidiaries 2,155,146 2,320,611 208,176 (4,683,933 ) — Noncurrent contingent consideration — 186,923 10,989 — 197,912 Other liabilities 148,572 7,850 12,442 — 168,864 Total liabilities 5,930,644 3,283,704 757,646 (6,221,033 ) 3,750,961 Total shareholders' equity 2,430,531 4,942,450 2,575,125 (7,517,575 ) 2,430,531 Total liabilities and shareholders' equity $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Three Months Ended April 1, 2018 Parent Guarantor Non-Guarantor Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (108,377 ) $ 134,198 $ 61,027 $ 86,848 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (159 ) (5,015 ) (10,573 ) (15,747 ) Payments for businesses and intangibles acquired, net of cash acquired — — (3,684 ) (3,684 ) Net cash used in investing activities from continuing operations (159 ) (5,015 ) (14,257 ) (19,431 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (18,500 ) — — (18,500 ) Debt extinguishment, issuance and amendment fees (74 ) — — (74 ) Net proceeds from share based compensation plans and the related tax impacts 1,400 — — 1,400 Payments for contingent consideration — (91 ) — (91 ) Dividends paid (15,447 ) — — (15,447 ) Intercompany transactions 131,967 (127,825 ) (4,142 ) — Net cash provided by (used in) financing activities from continuing operations 99,346 (127,916 ) (4,142 ) (32,712 ) Cash flows from discontinued operations: Net cash used in operating activities (206 ) — — (206 ) Net cash used in discontinued operations (206 ) — — (206 ) Effect of exchange rate changes on cash and cash equivalents — — 10,815 10,815 Net (decrease) increase in cash and cash equivalents (9,396 ) 1,267 53,443 45,314 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 333,558 Cash and cash equivalents at the end of the period $ 28,407 $ 10,200 $ 340,265 $ 378,872 Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (86,020 ) $ 158,343 $ 80,535 $ (61,918 ) $ 90,940 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (155 ) (2,206 ) (10,533 ) — (12,894 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — — — (975,524 ) Net cash used in investing activities from continuing operations (975,679 ) (2,206 ) (4,201 ) — (982,086 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (138,251 ) — — — (138,251 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts (505 ) — — — (505 ) Payments for contingent consideration — (79 ) — — (79 ) Dividends paid (15,287 ) — — — (15,287 ) Intercompany transactions 179,151 (149,496 ) (29,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,200,494 (149,575 ) (91,573 ) 61,918 1,021,264 Cash flows from discontinued operations: Net cash used in operating activities (266 ) — — — (266 ) Net cash used in discontinued operations (266 ) — — — (266 ) Effect of exchange rate changes on cash and cash equivalents — — 15,488 — 15,488 Net increase in cash and cash equivalents 138,529 6,562 249 — 145,340 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 153,100 $ 7,593 $ 528,436 $ — $ 689,129

Subsequent events - (Tables)

Subsequent events - (Tables)	3 Months Ended
	Apr. 01, 2018
Subsequent Events [Abstract]
Summary Of Current Cost Estimates By Major Type Of Cost Table	The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $60 million to $70 million Other exit costs (1) $2 million to $4 million Restructuring charges $62 million to $74 million Restructuring related charges (2) $40 million to $59 million Total restructuring and restructuring related charges $102 million to $133 million (1) Includes contract termination costs as well as facility closure and other exit costs (employee relocation costs, equipment relocation costs and outplacement). (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new location, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold.

New accounting standards (Detai

New accounting standards (Details) - USD ($) $ in Millions	Apr. 01, 2018	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract with customer, reverse for returns and allowances	$ 4.4
Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change on equity		$ 1.8
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings (Accumulated Deficit)		$ 0.3

Net revenues (Details)

Net revenues (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Concentration Risk [Line Items]
Reserve for returns and allowances	$ 4.4	$ 4.7
Reserve for the customer incentive programs, including distributor rebates	$ 13.2	$ 10.1
Sales Revenue, Net | Hospitals And Healthcare Providers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	87.00%
Sales Revenue, Net | Other Medical Device Manufacturers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	9.00%
Sales Revenue, Net | Home Care Providers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	4.00%

Net revenues Other revenues (De

Net revenues Other revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Revenue, Major Customer [Line Items]
Revenue	$ 587,230	$ 487,881
Vascular access
Revenue, Major Customer [Line Items]
Revenue	144,241	130,022
Anesthesia
Revenue, Major Customer [Line Items]
Revenue	85,418	81,205
Interventional
Revenue, Major Customer [Line Items]
Revenue	71,680	43,966
Surgical
Revenue, Major Customer [Line Items]
Revenue	85,632	87,304
Interventional urology
Revenue, Major Customer [Line Items]
Revenue	42,300	0
OEM
Revenue, Major Customer [Line Items]
Revenue	45,872	43,346
Other (3)
Revenue, Major Customer [Line Items]
Revenue	$ 112,087	$ 102,038

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($) $ in Thousands	Oct. 02, 2017	Dec. 31, 2017	Apr. 01, 2018	Feb. 17, 2017
Business Acquisition [Line Items]
Consideration transferred		$ 2,000,000
Contingent consideration liabilities		$ 272,136	$ 281,857
Aggregate milestone payment, maximum			400,400
Vascular Solutions, Inc.
Business Acquisition [Line Items]
Net assets acquired				$ 975,500
NeoTract
Business Acquisition [Line Items]
Consideration transferred	$ 975,200
Cash payment to acquire business	725,600
Business acquisition working capital adjustment	1,400
Contingent consideration liabilities	251,000
Aggregate milestone payment, maximum	$ 375,000		$ 375,000

Acquisitions - Pro Forma (Detai

Acquisitions - Pro Forma (Details) - Vascular Solutions, Inc. $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2017USD ($)$ / sharesshares
Business Acquisition [Line Items]
Net revenue | $	$ 533,318
Net income | $	$ 37,108
Net Income, Basic earnings per common share (in USD per share) | $ / shares	$ 0.83
Net Income, Diluted earnings per common share (in USD per share) | $ / shares	$ 0.80
Basic, weighted average common shares outstanding (in shares) | shares	44,893
Diluted, weighted average common shares outstanding (in shares) | shares	46,615

Restructuring charges - Charges

Restructuring charges - Charges Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,063	$ 12,945
Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,656	12,750
Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	407	195
Vascular Solutions Integration Program
Restructuring Cost and Reserve [Line Items]
Restructuring charges		4,482
Vascular Solutions Integration Program | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		4,482
Vascular Solutions Integration Program | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		0
EMEA Restructuring Program
Restructuring Cost and Reserve [Line Items]
Restructuring charges		7,121
EMEA Restructuring Program | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		7,121
EMEA Restructuring Program | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		0
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,149	509
2016 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,955	539
2016 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	194	(30)
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	124	311
2014 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	116	303
2014 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8	8
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	790	522
Other restructuring programs | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	585	305
Other restructuring programs | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 205	$ 217

Restructuring charges - Additio

Restructuring charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 6.5
Aggregate restructuring charges incurred	16.8
2016 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1.4	$ 2.1
Aggregate restructuring charges incurred	16.1
2016 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	34
Restructuring costs expected cash payment	27
2016 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	44
Restructuring costs expected cash payment	31
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	3.7
Restructuring expenses	27.3
Aggregate restructuring charges incurred	11.9
2014 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	0.4	$ 1.6
2014 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	46
Restructuring costs expected cash payment	38
Expected capital expenditures	24
2014 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	51
Restructuring costs expected cash payment	43
Expected capital expenditures	$ 30

Restructuring charges - Charg46

Restructuring charges - Charges by segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,063	$ 12,945
Vascular North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	321	728
Interventional North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	545	4,215
Anesthesia North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	34	247
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring charges	251	7,527
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,912	$ 228

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Apr. 01, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 94,786	$ 98,451
Work-in-process	66,185	62,381
Finished goods	242,705	234,912
Inventories, net	$ 403,676	$ 395,744

Goodwill and other intangible48

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	3 Months Ended
	Apr. 01, 2018USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,235,592
Goodwill related to acquisitions	157
Currency translation adjustment	28,698
Goodwill, ending balance	2,264,447
Vascular North America
Goodwill [Roll Forward]
Goodwill, beginning balance	264,869
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	264,869
Interventional North America
Goodwill [Roll Forward]
Goodwill, beginning balance	433,049
Goodwill related to acquisitions	0
Currency translation adjustment	5,630
Goodwill, ending balance	438,679
Anesthesia North America
Goodwill [Roll Forward]
Goodwill, beginning balance	157,289
Goodwill related to acquisitions	0
Currency translation adjustment	303
Goodwill, ending balance	157,592
Surgical North America
Goodwill [Roll Forward]
Goodwill, beginning balance	250,912
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	250,912
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	494,548
Goodwill related to acquisitions	9
Currency translation adjustment	16,225
Goodwill, ending balance	510,782
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	209,200
Goodwill related to acquisitions	3
Currency translation adjustment	4,048
Goodwill, ending balance	213,251
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	4,883
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	4,883
All Other
Goodwill [Roll Forward]
Goodwill, beginning balance	420,842
Goodwill related to acquisitions	145
Currency translation adjustment	2,492
Goodwill, ending balance	$ 423,479

Goodwill and other intangible49

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Apr. 01, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,016,337	$ 2,964,632
Accumulated Amortization	(625,782)	(580,884)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	31,698	34,672
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,044,509	1,023,837
Accumulated Amortization	(295,480)	(281,263)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,312,598	1,287,487
Accumulated Amortization	(282,907)	(258,580)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,922	23,697
Accumulated Amortization	(17,490)	(16,996)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	578,646	571,510
Accumulated Amortization	(25,990)	(22,069)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	24,964	23,429
Accumulated Amortization	$ (3,915)	$ (1,976)

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - USD ($)	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Net revenues	$ 587,230,000	$ 487,881,000
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Net revenues	38,300,000	31,500,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	0	0
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	117,300,000		$ 88,500,000
Foreign exchange contract | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Gain related to currency forward contracts	600,000
Loss related to currency forward contracts		$ 800,000
Total notional amount for all open foreign currency forward contracts	$ 111,500,000		$ 110,600,000

Financial instruments - Fair va

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Apr. 01, 2018	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 2,187	$ 1,221
Total liability derivatives	1,448	1,426
Foreign exchange contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,187	1,221
Foreign exchange contract | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	1,448	1,426
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	1,989	914
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	993	1,373
Foreign exchange contract | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	198	307
Foreign exchange contract | Not Designated as Hedging Instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 455	$ 53

Financial instruments - Aggrega

Financial instruments - Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	Apr. 01, 2018	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable	$ 9,865	$ 10,255
Allowance for doubtful accounts receivable, current	3,100	3,500
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal	$ 56,940	$ 49,054
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal	16.30%	14.60%
Long-term portion of accounts receivable, net	$ 3,700	$ 3,300

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Apr. 01, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 8,989	$ 9,045
Derivative assets	2,187	1,221
Derivative liabilities	1,448	1,426
Contingent consideration liabilities	281,857	272,136
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	8,989	9,045
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	2,187	1,221
Derivative liabilities	1,448	1,426
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 281,857	$ 272,136

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) - USD ($) $ in Millions	Apr. 01, 2018	Oct. 02, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate milestone payment, maximum	$ 400.4
NeoTract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate milestone payment, maximum	$ 375	$ 375

Fair value measurement - Valuat

Fair value measurement - Valuation technique and inputs used in determining the fair value of contingent consideration (Details)	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Contingent consideration, revenue volatility, percentage	21.10%

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	3 Months Ended
	Apr. 01, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 272,136
Payment	(91)
Revaluations	9,592
Translation adjustment	220
Ending balance	$ 281,857

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Shareholders Equity [Line Items]
Warrant or right, outstanding (in shares)	374,418
Investment warrants, exercise price (in dollars per share)	$ 74.65
Intrinsic value of warrants	$ 67.5
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	600,000	500,000

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Equity [Abstract]
Basic (in shares)	45,329	44,893
Dilutive effect of share-based awards (in shares)	1,044	821
DDilutive effect of convertible notes and warrants (in shares)	322	901
Diluted (in shares)	46,695	46,615

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 2,430,531
Other comprehensive income (loss) before reclassifications	82,051	$ 47,091
Amounts reclassified from accumulated other comprehensive income	639	2,509
Net current-period other comprehensive income	82,690	49,600
Ending Balance	2,560,500
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	340	(2,424)
Other comprehensive income (loss) before reclassifications	1,341	350
Amounts reclassified from accumulated other comprehensive income	(720)	1,378
Net current-period other comprehensive income	621	1,728
Ending Balance	961	(696)
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(138,808)	(136,596)
Other comprehensive income (loss) before reclassifications	(478)	(241)
Amounts reclassified from accumulated other comprehensive income	1,359	1,131
Net current-period other comprehensive income	881	890
Ending Balance	(137,927)	(135,706)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(126,623)	(299,697)
Other comprehensive income (loss) before reclassifications	81,188	46,982
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-period other comprehensive income	81,188	46,982
Ending Balance	(45,435)	(252,715)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(265,091)	(438,717)
Ending Balance	$ (182,401)	$ (389,117)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 255,960	$ 232,321
Total before tax	(61,173)	(37,680)
Taxes (benefit) on income from continuing operations	6,242	(2,669)
Net of tax	(54,931)	(40,349)
Total reclassifications, net of tax	639	2,509
Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,746	1,726
Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	24	29
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,770	1,755
Tax benefit	(411)	(624)
Total reclassifications, net of tax	1,359	1,131
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign exchange contract | Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(833)	1,645
Total before tax	(833)	1,645
Taxes (benefit) on income from continuing operations	113	(267)
Net of tax	$ (720)	$ 1,378

Taxes on income from continui61

Taxes on income from continuing operations (Details)	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Income Tax Disclosure [Abstract]
Effective income tax rate	10.20%	(7.10%)

Pension and other postretirem62

Pension and other postretirement benefits (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 378	$ 717
Interest cost	3,722	3,785
Expected return on plan assets	(7,421)	(6,743)
Net amortization and deferral	1,707	1,690
Net benefits expense (income)	(1,614)	(551)
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	52	74
Interest cost	378	378
Expected return on plan assets	0	0
Net amortization and deferral	62	65
Net benefits expense (income)	$ 492	$ 517

Commitments and contingent li63

Commitments and contingent liabilities (Detail) $ in Millions	3 Months Ended
	Apr. 01, 2018USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability	$ 1.8
Minimum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	15 years
Maximum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 1
Other Liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 5.7

Segment information (Details)

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 587,230	$ 487,881
Operating profit	86,843	60,819
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	113,044	90,581
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(26,201)	(29,762)
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	83,048	79,011
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	24,662	18,290
Interventional North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	60,196	39,946
Interventional North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	14,120	(8,035)
Anesthesia North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	50,565	48,207
Anesthesia North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	17,333	13,304
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	40,677	45,944
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	14,748	16,380
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	159,870	133,574
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	31,770	21,310
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	58,244	50,168
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	13,368	10,884
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	45,854	43,346
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	9,016	9,121
All other
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	88,776	47,685
All other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ (11,973)	$ 9,327

Segment information Total net r

Segment information Total net revenues by geographic region (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Segment Reporting Information [Line Items]
Net revenues	$ 587,230	$ 487,881
United States
Segment Reporting Information [Line Items]
Net revenues	344,357	286,314
Europe
Segment Reporting Information [Line Items]
Net revenues	171,320	141,022
Asia
Segment Reporting Information [Line Items]
Net revenues	49,555	43,004
All Other
Segment Reporting Information [Line Items]
Net revenues	$ 21,998	$ 17,541

Condensed consolidating guara66

Condensed consolidating guarantor financial information - Additional Information (Detail) - Senior Notes	Apr. 01, 2018USD ($)
Condensed Financial Statements Captions [Line Items]
Ownership percentage	100.00%
5.25% Senior Notes due 2024
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 250,000,000
Debt instrument, stated interest rate	5.25%
4.875% Senior Notes Due 2026
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 400,000,000
Debt instrument, stated interest rate	4.875%
4.625% Senior Notes due 2027
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 500,000,000
Debt instrument, stated interest rate	4.625%

Condensed consolidating guara67

Condensed consolidating guarantor financial information - Income and Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 587,230	$ 487,881
Cost of goods sold	255,960	232,321
Gross profit	331,270	255,560
Selling, general and administrative expenses	215,337	163,969
Research and development expenses	26,027	17,827
Restructuring charges	3,063	12,945
Income from continuing operations before interest, loss on extinguishment of debt and taxes	86,843	60,819
Interest, net	25,670	17,557
Loss on extinguishment of debt	0	5,582
Income from continuing operations before taxes	61,173	37,680
(Benefit) taxes on (loss) income from continuing operations	6,242	(2,669)
Equity in net income of consolidated subsidiaries	0	0
Income from continuing operations	54,931	40,349
Operating loss from discontinued operations	1,235	(282)
Benefit on loss from discontinued operations	(18)	(103)
Income (loss) from discontinued operations	1,253	(179)
Net income	56,184	40,170
Other comprehensive income	82,690	49,600
Comprehensive income	138,874	89,770
Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(112,198)	(104,077)
Cost of goods sold	(103,652)	(103,576)
Gross profit	(8,546)	(501)
Selling, general and administrative expenses	(529)	563
Research and development expenses	0	0
Restructuring charges	0	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(8,017)	(1,064)
Interest, net	0	0
Loss on extinguishment of debt		0
Income from continuing operations before taxes	(8,017)	(1,064)
(Benefit) taxes on (loss) income from continuing operations	(1,166)	524
Equity in net income of consolidated subsidiaries	(151,736)	(125,643)
Income from continuing operations	(158,587)	(127,231)
Operating loss from discontinued operations	0	0
Benefit on loss from discontinued operations	0	0
Income (loss) from discontinued operations	0	0
Net income	(158,587)	(127,231)
Other comprehensive income	(157,346)	(103,305)
Comprehensive income	(315,933)	(230,536)
Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0
Cost of goods sold	0	0
Gross profit	0	0
Selling, general and administrative expenses	9,181	20,519
Research and development expenses	227	235
Restructuring charges	0	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(9,408)	(20,754)
Interest, net	22,141	24,273
Loss on extinguishment of debt		5,582
Income from continuing operations before taxes	(31,549)	(50,609)
(Benefit) taxes on (loss) income from continuing operations	(13,192)	(21,333)
Equity in net income of consolidated subsidiaries	74,567	69,625
Income from continuing operations	56,210	40,349
Operating loss from discontinued operations	(44)	(282)
Benefit on loss from discontinued operations	(18)	(103)
Income (loss) from discontinued operations	(26)	(179)
Net income	56,184	40,170
Other comprehensive income	82,690	49,600
Comprehensive income	138,874	89,770
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	379,419	315,643
Cost of goods sold	217,604	192,001
Gross profit	161,815	123,642
Selling, general and administrative expenses	130,914	94,043
Research and development expenses	19,368	11,186
Restructuring charges	908	5,374
Income from continuing operations before interest, loss on extinguishment of debt and taxes	10,625	13,039
Interest, net	2,931	(7,562)
Loss on extinguishment of debt		0
Income from continuing operations before taxes	7,694	20,601
(Benefit) taxes on (loss) income from continuing operations	6,423	5,911
Equity in net income of consolidated subsidiaries	76,876	55,802
Income from continuing operations	78,147	70,492
Operating loss from discontinued operations	0	0
Benefit on loss from discontinued operations	0	0
Income (loss) from discontinued operations	0	0
Net income	78,147	70,492
Other comprehensive income	70,119	49,404
Comprehensive income	148,266	119,896
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	320,009	276,315
Cost of goods sold	142,008	143,896
Gross profit	178,001	132,419
Selling, general and administrative expenses	75,771	48,844
Research and development expenses	6,432	6,406
Restructuring charges	2,155	7,571
Income from continuing operations before interest, loss on extinguishment of debt and taxes	93,643	69,598
Interest, net	598	846
Loss on extinguishment of debt		0
Income from continuing operations before taxes	93,045	68,752
(Benefit) taxes on (loss) income from continuing operations	14,177	12,229
Equity in net income of consolidated subsidiaries	293	216
Income from continuing operations	79,161	56,739
Operating loss from discontinued operations	1,279	0
Benefit on loss from discontinued operations	0	0
Income (loss) from discontinued operations	1,279	0
Net income	80,440	56,739
Other comprehensive income	87,227	53,901
Comprehensive income	$ 167,667	$ 110,640

Condensed consolidating guara68

Condensed consolidating guarantor financial information - Balance Sheets (Details) - USD ($) $ in Thousands	Apr. 01, 2018	Dec. 31, 2017	Apr. 02, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 378,872	$ 333,558	$ 689,129	$ 543,789
Accounts receivable, net	359,140	345,875
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	403,676	395,744
Prepaid expenses and other current assets	52,998	47,882
Prepaid taxes	7,234	5,748
Assets held for sale	3,239	0
Total current assets	1,205,159	1,128,807
Property, plant and equipment, net	389,519	382,999
Goodwill	2,264,447	2,235,592
Intangible assets, net	2,390,555	2,383,748
Investments in consolidated subsidiaries	0	0
Deferred tax assets	3,969	3,810
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	46,951	46,536
Total assets	6,300,600	6,181,492
Current liabilities
Current borrowings	77,500	86,625
Accounts payable	84,686	92,027
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	101,128	96,853
Current portion of contingent consideration	162,061	74,224
Payroll and benefit-related liabilities	80,418	107,415
Accrued interest	20,503	6,165
Income taxes payable	13,500	11,514
Other current liabilities	11,978	9,053
Total current liabilities	551,774	483,876
Long-term borrowings	2,154,217	2,162,927
Deferred tax liabilities	616,711	603,676
Pension and postretirement benefit liabilities	117,874	121,410
Noncurrent liability for uncertain tax positions	12,628	12,296
Notes payable and other amounts due to consolidated subsidiaries	0	0
Noncurrent contingent consideration	119,796	197,912
Other liabilities	167,100	168,864
Total liabilities	3,740,100	3,750,961
Total shareholders' equity	2,560,500	2,430,531
Total liabilities and shareholders' equity	6,300,600	6,181,492
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	5,192	4,663
Accounts receivable from consolidated subsidiaries	(1,366,548)	(1,534,839)
Inventories, net	(34,956)	(26,279)
Prepaid expenses and other current assets	3,982	3,982
Prepaid taxes	0	0
Assets held for sale	0
Total current assets	(1,392,330)	(1,552,473)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investments in consolidated subsidiaries	(7,811,539)	(7,499,941)
Deferred tax assets	(2,261)	(2,261)
Notes receivable and other amounts due from consolidated subsidiaries	(4,360,995)	(4,683,933)
Other assets	0	0
Total assets	(13,567,125)	(13,738,608)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(1,366,548)	(1,534,839)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	(1,166)	0
Other current liabilities	0	0
Total current liabilities	(1,367,714)	(1,534,839)
Long-term borrowings	0	0
Deferred tax liabilities	(2,261)	(2,261)
Pension and postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due to consolidated subsidiaries	(4,360,995)	(4,683,933)
Noncurrent contingent consideration	0	0
Other liabilities	0	0
Total liabilities	(5,730,970)	(6,221,033)
Total shareholders' equity	(7,836,155)	(7,517,575)
Total liabilities and shareholders' equity	(13,567,125)	(13,738,608)
Parent Company
Current assets
Cash and cash equivalents	28,407	37,803	153,100	14,571
Accounts receivable, net	2,822	2,414
Accounts receivable from consolidated subsidiaries	25,239	14,478
Inventories, net	0	0
Prepaid expenses and other current assets	15,470	14,874
Prepaid taxes	0	0
Assets held for sale	0
Total current assets	71,938	69,569
Property, plant and equipment, net	2,340	2,088
Goodwill	0	0
Intangible assets, net	0	0
Investments in consolidated subsidiaries	5,963,828	5,806,244
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,171,364	2,452,101
Other assets	30,864	31,173
Total assets	8,240,334	8,361,175
Current liabilities
Current borrowings	27,500	36,625
Accounts payable	2,954	4,269
Accounts payable to consolidated subsidiaries	1,014,612	1,211,568
Accrued expenses	20,314	17,957
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	15,618	21,145
Accrued interest	20,463	6,133
Income taxes payable	936	4,352
Other current liabilities	1,466	1,461
Total current liabilities	1,103,863	1,303,510
Long-term borrowings	2,154,217	2,162,927
Deferred tax liabilities	88,632	88,512
Pension and postretirement benefit liabilities	66,986	70,860
Noncurrent liability for uncertain tax positions	1,396	1,117
Notes payable and other amounts due to consolidated subsidiaries	2,114,287	2,155,146
Noncurrent contingent consideration	0	0
Other liabilities	150,453	148,572
Total liabilities	5,679,834	5,930,644
Total shareholders' equity	2,560,500	2,430,531
Total liabilities and shareholders' equity	8,240,334	8,361,175
Guarantor Subsidiaries
Current assets
Cash and cash equivalents	10,200	8,933	7,593	1,031
Accounts receivable, net	35,826	57,818
Accounts receivable from consolidated subsidiaries	994,384	1,177,246
Inventories, net	246,289	245,533
Prepaid expenses and other current assets	12,482	9,236
Prepaid taxes	0	0
Assets held for sale	3,239
Total current assets	1,302,420	1,498,766
Property, plant and equipment, net	205,115	213,663
Goodwill	1,247,150	1,246,144
Intangible assets, net	1,333,983	1,355,275
Investments in consolidated subsidiaries	1,827,988	1,674,077
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,189,631	2,231,832
Other assets	6,426	6,397
Total assets	8,112,713	8,226,154
Current liabilities
Current borrowings	0	0
Accounts payable	45,416	46,992
Accounts payable to consolidated subsidiaries	275,625	261,121
Accrued expenses	33,152	31,827
Current portion of contingent consideration	162,061	74,224
Payroll and benefit-related liabilities	24,212	44,009
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	5,355	3,775
Total current liabilities	545,821	461,948
Long-term borrowings	0	0
Deferred tax liabilities	270,305	265,426
Pension and postretirement benefit liabilities	32,393	32,750
Noncurrent liability for uncertain tax positions	8,237	8,196
Notes payable and other amounts due to consolidated subsidiaries	2,048,841	2,320,611
Noncurrent contingent consideration	108,727	186,923
Other liabilities	5,802	7,850
Total liabilities	3,020,126	3,283,704
Total shareholders' equity	5,092,587	4,942,450
Total liabilities and shareholders' equity	8,112,713	8,226,154
Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	340,265	286,822	$ 528,436	$ 528,187
Accounts receivable, net	315,300	280,980
Accounts receivable from consolidated subsidiaries	346,925	343,115
Inventories, net	192,343	176,490
Prepaid expenses and other current assets	21,064	19,790
Prepaid taxes	7,234	5,748
Assets held for sale	0
Total current assets	1,223,131	1,112,945
Property, plant and equipment, net	182,064	167,248
Goodwill	1,017,297	989,448
Intangible assets, net	1,056,572	1,028,473
Investments in consolidated subsidiaries	19,723	19,620
Deferred tax assets	6,230	6,071
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	9,661	8,966
Total assets	3,514,678	3,332,771
Current liabilities
Current borrowings	50,000	50,000
Accounts payable	36,316	40,766
Accounts payable to consolidated subsidiaries	76,311	62,150
Accrued expenses	47,662	47,069
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	40,588	42,261
Accrued interest	40	32
Income taxes payable	13,730	7,162
Other current liabilities	5,157	3,817
Total current liabilities	269,804	253,257
Long-term borrowings	0	0
Deferred tax liabilities	260,035	251,999
Pension and postretirement benefit liabilities	18,495	17,800
Noncurrent liability for uncertain tax positions	2,995	2,983
Notes payable and other amounts due to consolidated subsidiaries	197,867	208,176
Noncurrent contingent consideration	11,069	10,989
Other liabilities	10,845	12,442
Total liabilities	771,110	757,646
Total shareholders' equity	2,743,568	2,575,125
Total liabilities and shareholders' equity	$ 3,514,678	$ 3,332,771

Condensed consolidating guara69

Condensed consolidating guarantor financial information - Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 86,848	$ 90,940
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(15,747)	(12,894)
Proceeds from sale of assets and investments	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(3,684)	(975,524)
Net cash used in investing activities from continuing operations	(19,431)	(982,086)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	1,194,500
Reduction in borrowings	(18,500)	(138,251)
Debt extinguishment, issuance and amendment fees	(74)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	1,400	(505)
Payments for contingent consideration	(91)	(79)
Dividends paid	(15,447)	(15,287)
Intercompany transactions	0	0
Intercompany dividends paid		0
Net cash provided by (used in) financing activities from continuing operations	(32,712)	1,021,264
Cash flows from discontinued operations:
Net cash used in operating activities	(206)	(266)
Net cash used in discontinued operations	(206)	(266)
Effect of exchange rate changes on cash and cash equivalents	10,815	15,488
Net increase in cash and cash equivalents	45,314	145,340
Cash and cash equivalents at the beginning of the period	333,558	543,789
Cash and cash equivalents at the end of the period	378,872	689,129
Eliminations
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations		(61,918)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment		0
Proceeds from sale of assets and investments		0
Payments for businesses and intangibles acquired, net of cash acquired		0
Net cash used in investing activities from continuing operations		0
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings		0
Debt extinguishment, issuance and amendment fees		0
Net proceeds from share based compensation plans and the related tax impacts		0
Payments for contingent consideration		0
Dividends paid		0
Intercompany transactions		0
Intercompany dividends paid		61,918
Net cash provided by (used in) financing activities from continuing operations		61,918
Cash flows from discontinued operations:
Net cash used in operating activities		0
Net cash used in discontinued operations		0
Effect of exchange rate changes on cash and cash equivalents		0
Net increase in cash and cash equivalents		0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(108,377)	(86,020)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(159)	(155)
Proceeds from sale of assets and investments		0
Payments for businesses and intangibles acquired, net of cash acquired	0	(975,524)
Net cash used in investing activities from continuing operations	(159)	(975,679)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		1,194,500
Reduction in borrowings	(18,500)	(138,251)
Debt extinguishment, issuance and amendment fees	(74)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	1,400	(505)
Payments for contingent consideration	0	0
Dividends paid	(15,447)	(15,287)
Intercompany transactions	131,967	179,151
Intercompany dividends paid		0
Net cash provided by (used in) financing activities from continuing operations	99,346	1,200,494
Cash flows from discontinued operations:
Net cash used in operating activities	(206)	(266)
Net cash used in discontinued operations	(206)	(266)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	(9,396)	138,529
Cash and cash equivalents at the beginning of the period	37,803	14,571
Cash and cash equivalents at the end of the period	28,407	153,100
Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	134,198	158,343
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(5,015)	(2,206)
Proceeds from sale of assets and investments		0
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Net cash used in investing activities from continuing operations	(5,015)	(2,206)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(91)	(79)
Dividends paid	0	0
Intercompany transactions	(127,825)	(149,496)
Intercompany dividends paid		0
Net cash provided by (used in) financing activities from continuing operations	(127,916)	(149,575)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	1,267	6,562
Cash and cash equivalents at the beginning of the period	8,933	1,031
Cash and cash equivalents at the end of the period	10,200	7,593
Non-Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	61,027	80,535
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(10,573)	(10,533)
Proceeds from sale of assets and investments		6,332
Payments for businesses and intangibles acquired, net of cash acquired	(3,684)	0
Net cash used in investing activities from continuing operations	(14,257)	(4,201)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	(4,142)	(29,655)
Intercompany dividends paid		(61,918)
Net cash provided by (used in) financing activities from continuing operations	(4,142)	(91,573)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	10,815	15,488
Net increase in cash and cash equivalents	53,443	249
Cash and cash equivalents at the beginning of the period	286,822	528,187
Cash and cash equivalents at the end of the period	$ 340,265	$ 528,436

Subsequent events Cost estimate

Subsequent events Cost estimates by major type of expense (Details) - Subsequent Event - 2018 Footprint Realignment Plan $ in Millions	May 01, 2018USD ($)
Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 102
Minimum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	60
Minimum | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2
Minimum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	62
Minimum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	40
Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	133
Maximum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	70
Maximum | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4
Maximum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	74
Maximum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 59

Subsequent events (Details)

Subsequent events (Details) - 2018 Footprint Realignment Plan - Subsequent Event $ in Millions	May 01, 2018USD ($)
Minimum
Subsequent Event [Line Items]
Restructuring costs expected cash payment	$ 99
Expected capital expenditures	19
Maximum
Subsequent Event [Line Items]
Restructuring costs expected cash payment	127
Expected capital expenditures	$ 23

Uncategorized Items - tfx-20180

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 2,110,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 2,110,000